Vimal Kumar

Vimal Kumar

Auto-generated profile, based on publicly available information

Vimal Kumar

Department of Pediatric Hematology, Oncology & BMT, MGM Cancer Institute, Chennai, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2021 in Fetal and Pediatric Pathology
Verified
Journal Article
Closed access
Mukul vijMukul vij
Mukul vij
MSMeena Sivasankaran
Meena Sivasankaran
DJDhaarani Jayaraman
Dhaarani Jayaraman
SSSrinivas Sankaranarayanan
Srinivas Sankaranarayanan
VKVimal Kumar
Vimal Kumar
JSJulius Scott
Julius Scott
Background: Primary immunodeficiency (PID) having defects related to lymphocyte cytotoxic pathway or T-cell dysfunction are well known for developing opportunistic infections and Epstein-Barr virus (EBV)-associated diseases. CARMIL2 deficiency is a recently described combined immunodeficiency (CID) disorder characterized by defective CD28-mediated T cell co-stimulation, altered cytoskeletal dynamics, susceptibility to various infections and Epstein Barr Virus smooth muscle tumor (EBV-SMT). Case report: We report a homozygous CARMIL2 pathogenic variant presenting with recurrent infections and EBV associated smooth muscle tumor (SMT) in a child. Conclusion: The present study reports that EBV SMT may occur in a child with CARMIL2 deficiency.

1 November 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
JMJagadeesh Menon
Jagadeesh Menon
NSNaresh Shanmugam
Naresh Shanmugam
JVJoseph Valamparampil
Joseph Valamparampil
Mukul vijMukul vij
Mukul vij
VKVimal Kumar
Vimal Kumar
MRMohamed Rela
Mohamed Rela

17 October 2017 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
VKVimal Kumar
Vimal Kumar
DADhanalakshmi Angappan
Dhanalakshmi Angappan
JSJulius Scott
Julius Scott
DMDeenadayalan Munirathnam
Deenadayalan Munirathnam
MVMukul Vij
Mukul Vij
NSNaresh Shanmugam
Naresh Shanmugam

28 March 2021 in Indian Pediatrics
Verified
Journal Article
Closed access
PDF file
DMDeenadayalan Munirathnam
Deenadayalan Munirathnam
VKVimal Kumar
Vimal Kumar
MSMeena Sivasankaran
Meena Sivasankaran
SASilky Agrawal
Silky Agrawal

9 February 2014 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Open access
PDF file
RRRevathi Raj
Revathi Raj
MDM. Deenadayalan
M. Deenadayalan
GKG. Vimal Kumar
G. Vimal Kumar
VKVipin Khandelwal
Vipin Khandelwal
KSKaruna Sri
Karuna Sri
THTerunuma Hiroshi
Terunuma Hiroshi
Advances in current treatment regimens in childhood acute lymphoblastic leukemia (ALL) have resulted in cure rates of 75–80 %. Some molecular genetic abnormalities confer a poor prognosis. Of these, the chromosomal translocation t (9;22)—Philadelphia chromosome is associated with the worst outcome in childhood ALL. Optimal therapy for this variant of ALL includes chemotherapy as per high risk schedule, imatinib and early stem cell transplantation. We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL.

8 April 2016 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Open access
PDF file
RURamya Uppuluri
Ramya Uppuluri
VKVimal Kumar
Vimal Kumar
DMDeenadayalan Munirathnam
Deenadayalan Munirathnam
HDHemalatha Doss
Hemalatha Doss
SRSreejith Ramachandrakurup
Sreejith Ramachandrakurup
RRRevathi Raj
Revathi Raj
Kaposiform hemangioendothelioma is a rare, highly vascular and aggressive soft tissue tumor frequently associated with Kasabach–Merritt phenomenon, usually seen in early infancy. Early diagnosis by means of MRI and tissue biopsy portends a better outcome. Treatment includes surgical excision when feasible and medical management with steroids, propranolol, vincristine and supportive treatment for coagulopathy. We report a 3 months old female infant who was diagnosed, treated successfully and is now in complete remission.